Traders purchased shares of Merck & Company, Inc. (NYSE:MRK) on weakness during trading hours on Tuesday. $105.76 million flowed into the stock on the tick-up and $55.04 million flowed out of the stock on the tick-down, for a money net flow of $50.72 million into the stock. Of all equities tracked, Merck & had the 13th highest net in-flow for the day. Merck & traded down ($0.21) for the day and closed at $63.62

Several brokerages recently commented on MRK. Credit Suisse Group set a $72.00 price target on Merck & and gave the stock a “buy” rating in a research report on Tuesday, June 6th. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Vetr cut Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 price target for the company. in a research report on Wednesday, May 17th. Zacks Investment Research upgraded Merck & from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a research report on Wednesday, May 10th. Finally, Cowen and Company reiterated a “hold” rating and set a $70.00 price target on shares of Merck & in a research report on Friday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. Merck & currently has an average rating of “Hold” and a consensus price target of $69.74.

The company has a market cap of $173.51 billion, a P/E ratio of 34.45 and a beta of 0.81. The stock’s 50 day moving average price is $62.84 and its 200-day moving average price is $63.72.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the previous year, the firm posted $0.93 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Merck & Company, Inc. will post $3.88 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.

Several large investors have recently bought and sold shares of MRK. Krilogy Financial LLC grew its holdings in Merck & by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after buying an additional 11 shares in the last quarter. HM Capital Management LLC grew its holdings in Merck & by 0.4% in the 1st quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after buying an additional 15 shares in the last quarter. Balentine LLC grew its holdings in Merck & by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after buying an additional 20 shares in the last quarter. RB Capital Management LLC grew its holdings in Merck & by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares in the last quarter. Finally, Baystate Wealth Management LLC grew its holdings in Merck & by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares in the last quarter. 73.02% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Traders Buy Shares of Merck & Company, Inc. (MRK) on Weakness” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/05/traders-buy-shares-of-merck-company-inc-mrk-on-weakness-2.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.